Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.

Peng LF, Schaefer EA, Maloof N, Skaff A, Berical A, Belon CA, Heck JA, Lin W, Frick DN, Allen TM, Miziorko HM, Schreiber SL, Chung RT.

J Infect Dis. 2011 Aug 15;204(4):609-16. doi: 10.1093/infdis/jir303.

2.

Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.

Ikeda M, Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N.

Liver Int. 2011 Jul;31(6):871-80. doi: 10.1111/j.1478-3231.2011.02499.x. Epub 2011 Mar 13.

PMID:
21645219
3.

A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.

Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, Ikeda M, Schreiber SL, Chung RT.

Gastroenterology. 2007 Jan;132(1):311-20. Epub 2006 Oct 21. Erratum in: Gastroenterology. 2007 Aug;133(2):730. Gastroenterology. 2007 Mar;132(3):1208. Kato, Nobuyuki [added]; Ikeda, Masanori [added]. Gastroenterology. 2007 May;132(5):2082.

PMID:
17241881
4.

Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.

Saito K, Shirasago Y, Suzuki T, Aizaki H, Hanada K, Wakita T, Nishijima M, Fukasawa M.

J Virol. 2015 Feb;89(4):2220-32. doi: 10.1128/JVI.03385-14. Epub 2014 Dec 3.

5.

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N.

Hepatology. 2006 Jul;44(1):117-25.

PMID:
16799963
7.

Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.

Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, Frank R, Pietschmann T.

Antiviral Res. 2011 Feb;89(2):136-48. doi: 10.1016/j.antiviral.2010.12.005. Epub 2010 Dec 15.

PMID:
21167208
8.

Are statins a viable option for the treatment of infections with the hepatitis C virus?

Verpaalen B, Neyts J, Delang L.

Antiviral Res. 2014 May;105:92-9. doi: 10.1016/j.antiviral.2014.02.020. Epub 2014 Mar 6.

PMID:
24613180
10.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

11.

A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3.

Niu Y, Si Y, Li Y, Chi X, Li X, Liu X, Li D, Cheng M, Fan J, Si S, Yang W.

J Antimicrob Chemother. 2015 Jul;70(7):2013-23. doi: 10.1093/jac/dkv077. Epub 2015 Apr 8.

PMID:
25858355
12.

Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.

Kaushik-Basu N, Ratmanova NK, Manvar D, Belov DS, Cevik O, Basu A, Yerukhimovich MM, Lukyanenko ER, Andreev IA, Belov GM, Manfroni G, Cecchetti V, Frick DN, Kurkin AV, Altieri A, Barreca ML.

Eur J Med Chem. 2016 Oct 21;122:319-325. doi: 10.1016/j.ejmech.2016.06.041. Epub 2016 Jun 23.

PMID:
27376494
13.

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.

Leivers AL, Tallant M, Shotwell JB, Dickerson S, Leivers MR, McDonald OB, Gobel J, Creech KL, Strum SL, Mathis A, Rogers S, Moore CB, Botyanszki J.

J Med Chem. 2014 Mar 13;57(5):2091-106. doi: 10.1021/jm400781h. Epub 2013 Aug 14.

PMID:
23944386
14.

Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.

Nakajima S, Watashi K, Ohashi H, Kamisuki S, Izaguirre-Carbonell J, Kwon AT, Suzuki H, Kataoka M, Tsukuda S, Okada M, Moi ML, Takeuchi T, Arita M, Suzuki R, Aizaki H, Kato T, Suzuki T, Hasegawa H, Takasaki T, Sugawara F, Wakita T.

J Virol. 2016 Sep 29;90(20):9058-74. doi: 10.1128/JVI.00856-16. Print 2016 Oct 15.

15.

Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.

Jin G, Lee S, Choi M, Son S, Kim GW, Oh JW, Lee C, Lee K.

Eur J Med Chem. 2014 Mar 21;75:413-25. doi: 10.1016/j.ejmech.2014.01.062. Epub 2014 Jan 31.

PMID:
24561671
16.

Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699.

Greenspan MD, Yudkovitz JB, Lo CY, Chen JS, Alberts AW, Hunt VM, Chang MN, Yang SS, Thompson KL, Chiang YC, et al.

Proc Natl Acad Sci U S A. 1987 Nov;84(21):7488-92.

17.
18.

Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT.

Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, Chen JC, Liu YW.

Int J Mol Med. 2012 Nov;30(5):1021-8. doi: 10.3892/ijmm.2012.1096. Epub 2012 Aug 20.

19.

Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.

Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung RT, Onji M.

Hepatology. 2008 Jul;48(1):59-69. doi: 10.1002/hep.22289.

PMID:
18459156
20.

Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.

Munakata T, Inada M, Tokunaga Y, Wakita T, Kohara M, Nomoto A.

Antiviral Res. 2014 Aug;108:79-87. doi: 10.1016/j.antiviral.2014.05.011. Epub 2014 Jun 2.

PMID:
24893207

Supplemental Content

Support Center